Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Because it was dirt cheap since they were in dire straights of going under.
Why don't you explain why we went from under .80 to over $3 a share with no fundamental changes in the company balance sheet?
We can all throw out vague dumb questions, but the smarter people see through your FUD and know the answers.
How long have you been taking this much?
Any issues?
I am in my first few weeks, but was planning on reordering and possibly wanted to move up from 2 grams a day.
Thanks in advance for your answer.
BioChia turned me on to PharmaEPA both Restore and Maintain products.
I just purchased each and have been trying them for the last couple of weeks. I am not sure how long BioChia has been using them.
So far I am very impressed with the product ordered from Amazon. No fish burps or fish taste at all even on an empty stomach.
Both BioChia and myself agree after cutting one open you do not smell a fishy stink at all there is only the smell of lemon, which I think they are using to stop the oil from oxidizing. I them took the cut open pill and oil and put them in warm to hot water. Only then could I smell fish like smelling a fresh piece of wild salmon from the store. The smell was not like a heavy rancid smell as if the fish from the store was old or the DS you get from Walmart and the likes.
As for price:
You need two boxes of Restore which is 4 pills a day or 2 grams of EPA for a month supply. $38 a box of 60.
The Maintain product requires 3 pills a day for 750 mg. of EPA and 250 mg. of DHA, which would require 1.5 boxes for a month supply.
However, my daughter is only taking two pills right now for 500 mg. of EPA and 125 mg. of DHA which is two pills a day and one box is a month supply. $24 a box of 60.
Hope this helps,
Not that I know of, but thank you for sharing your experience.
I have a case study of one on this very subject. My Mother has been on Vascepa by my recommendation for about a year. Her Doctor would only prescribe her two grams but that is another story for another time. When she started taking Vascepa her doctor had labeled her as a walking time bomb. Because no matter what he tried he could not get her LDL-C and TG below approximately 250. He tried every statin out there, fenofibrates and niacin. They finally settled on the only thing tolerable by her was pitavastatin generic. Again with this treatment he could not get her numbers down. So she started taking it about 3 months before her visit to the cardiologist and after three months not much had changed with her numbers other than her TG had come down a bit. Then she had another appointment about 6 to 7 months later with no changes to diet, exercise, or medication. She just recently revealed to me that all of her numbers are now fully lowered to where her cardiologist is very happy and impressed.
So for her the pitavastatin alone could not get her LDL-C numbers down, and again she could not tolerate any other statin, but did not try Livalo. When she added Vasepa to the mix that is when all of her numbers came down after about 10 months of 2 grams a day.
Hope this helps,
Thank you again everyone for all your input on helping me with my daughters ADHD and choosing a supplement all great suggestions.
Zumantu
I will bring your info to the doc at her next office visit, but am going to try something until then to see what kind of results I get with her.
ORBAPU
Here is the funny thing my daughter is my healthy eater and my son who is smart as a whip eats as much junk as he can find. Go figure.
Pharmacydude
Can you share the supplement you used for your kids and the dosage.
TY
First of all a big Thank you to Zumantu, BioChica, and Pharmacydude for the info I have been wanting to try something for my 10 year old daughter diagnosed with ADHD and taking meds.
Orbapu,
Couple of questions for you:
1) Do you order from Amazon or directly from OmegaVia?
2) Is there any fishy smell meaning oxidation?
Thanks in advance for your reply,
"At the time of the preliminary analysis, the evacetrapib group had mean HDL of 104 mg/dL vs. 46 mg/dL for the placebo group (mean difference, 130%), according to Nicholls.
Mean LDL levels were 55 mg/dL in the evacetrapib group and 84 mg/dL in the placebo group (mean difference, 37%), he said."
Ok so the way I read this is that there is no benefit to having your LDL below 100 or even further below 100 and also no benefit in raising your HDL.
So Kiwi and Ajax as far as I know where the ones saying injections treatments are the wave of the future and going to be the highest selling drug of all time. Hmmmmm.
Oh but wait lowering your LDL to new levels below 100 has no benefit. Going to be tough to get insurance to cover this large expense for the high cholesterol population. So like many of us said it is going to be restricted to the hyper cholesterol cases only.
You wrote:
"The timing of an interim look later than today's date put's efficacy > 15% even if you consider an unrealistic placebo rate way less than 5.2%. At 5.2% placebo rate efficacy will hover around 40%. This is greater than many not as well run statin trials. The life cycle of Vascepa is defined...greater than $100 Billion life cycle."
Great reply but I am not so sure Wall Street believes this boards statistical analysis as much as we all do here (excluding Mog, kiwi, ladavis). So does Wall Street wait for interum analysis to remove any doubt?
OR
Is Wall street now starting to run there own statistical analysis now that the 967 event is upon us and will they see the light and start to buy in as I believe you are stating?
Well at least we are both in the no NCE camp and I can see it being used as a bargaining chip to gain anchor SPA.
Thanks for the replies always a pleasure.
Three things.
1) Why would the stock price change now as the company has informed investors especially shorts that they still have six months to play before some clarification on RI?
2) Lets entertain for a minute your idea for them to litigate SPA rescinding with the FDA. I would think and correct me if I am wrong with the interim analysis they could finish the appealing process within the FDA all the way up to the director of the FDA before they would litigate in court, or did they sign off on that with the FDA? I thought they reserved there right to continue the appeals process with the FDA but I can't remember? Does RI interim analysis continue decision by the DMC allow there argument to be stronger for this appeals process with the the FDA?
(I am using continue here as we all know if a stop occurs what will happen)
3) I am thinking we will never hear an NCE decision as now the FDA has cause to delay more with a difference between Moss saying you do not have the power to change the meaning of moiety versus ingredient and now a DC judge saying they do have the ability to do such.
Dang Irish holidays I completely forgot, but with a massive hangover then why the 18th?
Well you might be onto something as the date March 18th is the date that NCE gets updated in march and the following day is the first day of spring.
(This would jive with the company not trusting the FDA as far as they can throw them.)
Also why not just say another 30 days/month which would be march 17th and why only a month this time instead of the standard two?
Also add the fact that the SPA is still an open item, and this will be going on 7 months now.
One more thing is this does barely get it done before April 1.
Hmmmmmmmmmmmm.
It will be interesting on the 18th if we get NCE completed and then after market close we get a settlement disclosure.
Also hoping in the CC we get info that interim has not yet occurred and get a better timeline as to when.
I will not make any predictions as to what the settlement might be.
Thanks for the updates and interesting posts.
Unfortunately, I do not think NCE will be this Friday(being Lincoln's B-day and we all know what happened to him), So I agree another delay is in order. However, next month NCE Friday(following day is the first day of spring) so I guess this puts me in HDG NCE beliefs group.
I would gladly be wrong and have this Friday be the day Mogwash gets the Lincoln treatment and is pushing up flowers next month.
Sometime between now and Feb. 17th 2016. Everyone knows that.
Actually I was reading Stocktwits for a laugh and there was a guy on there saying he used to get really bad gout attacks, but since being on V for the last three years none. FYI.
Well look at the pot calling the kettle black.
Um you might not want to forget about this little gem:
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20060111437.PGNR.
Also they did conduct the CHERRY study and have been pouring over the data.
JL I agree with you but have a slightly different reading of the tea leaves.
Yes absolutely avoid another stock holder law suit when discussing Reduce-it completion.
I am thinking by what was stated today that the label changed is more probable by December, which is exactly what Lovaza got with out running a trial and a great way to fend off Fibrates and Niacin for Anchor population.
Why press the FDA for the SPA to be reinstated by December when it can and will be brought up at interim. Possibly only a few more months away and possibly a provision of the settlement with the FDA?
Reduce-it trial enrollment was tracking at 100 per quarter, but now they are going to enroll the last 200 or so by the end of the year. Hmmmm, why the speed up if you think interim will not occur until second quarter 2016? I would think they want the trial fully enrolled before interim, and this may signal interim will come in the first quarter like HD predicted, also this may be a provision of the settlement with the FDA?
I will state this again as I was poo-pooed by sts66 about more partnerships/contracts being to difficult to clean up if bought out by a BP. The company stated they are still in talks and I am sure dragging there feet until interim, which will possibly make for much more lucrative contracts. Also may occur in first quarter of 2016 as previously stated.
These goals all seem attainable by December and first quarter 2016, and would be quite a savy move for a level headed management team.
JL great post and I wanted to add one more thing to it if I may. If the company is really feeling interim results maybe in there favor for a possible stop and you have enough cash to get you to interim safely.
Would you be signing any more overseas deals that you do not have to have right away or do you hold off for interim results? Risky to hold off but the deals will be much more lucrative if interim goes our way.
Wow you should change your handle to "Negative Nancy".
Ops I mean "The Real Negative Nancy".
If anyone can do it why are we yet to see anything of the sort from you?
HDG,
Thank you for your help getting the facts straight. You are a gentleman and a scholar.
sts66,
The Matina's patent states the following:
The present invention provides a pharmaceutical composition comprising eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA), wherein the amount of EPA and DPA is about 55% or more by weight of the total amount of fatty acids, and wherein the ratio of DHA:DPA is no more than 1:1. The present invention also provides a pharmaceutical composition comprising eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA), wherein the amount of EPA and DPA is about 55% or more by weight of the total amount of fatty acids, and wherein the ratio of DHA:DPA is no more than 1:1.
So there mix is EPA, DHA, and DPA sames as what Epanova has a patent for in the OB. So I have to agree with this guy that they get no NME or NCE. However perhaps they are not concerned with this as DPA is in short supply and they are the only ones with a propriety method that can synthesize it? What does this cost?
I would also agree with him that they would have to run there own CVOT since DPA is something new to the mix. I mean if Lovaza ran a CVOT and it was successful do you think Vascepa as EPA only could have piggy backed off of it.
I believe you are right it was discussed on this board on how we have Epanova locked out and I think I remember it is on the raising LDL-C 20% or more, but that would not hold true for MAT-90001.
This is one of the better reads I have found on yahoo amrn message board with a buzillion knuckle heads blocked.
It is a retort to the latest Zack's article on yahoo touting MTNB.
MAT90001 got it's patent for 15 years in 2014. They still have to run a phase 3 trial later this year and apply for FDA approval which basically means they probably will not be able to sell into the marine market with approval until 2017. By then the results of Vascepa Reduce-it trial will be know with final results in 2018.
For arguments sake lets say both the phase 3 for MAT90001 and Reduce-it trial for Vascepa are both successful, which is mainly why you would invest in either stock.
So in 2017 Vascepa has a successful Reduce-it trial and is the only omega 3 drug selling in the 150 to Marine(500+) trig population and MAT90001 is still only approved for Marine with Lovaza and Generic Lovaza. As you can see it has taken Vascepa three years to get to it's current sales shown in the article with a small sales force. How long will it take MAT90001 to achieve this with a tiny sales force? Also Vascepa has numerous studies in it's favor for EPA intake, and MAT90001 has none for it's intake of DPA, because this is the first time large amounts of DPA can be synthesized and put in a drug. Yes it may reduce trigs, but what about the bigger picture of reducing CVD a total unknown for MAT90001.
So now with Vascepa out and chewing up market share a BP is supposed to put over 100 million into a five year trial plus a year data review for MAT90001. So that takes us from 2018 which is the earliest it could get a trial started to 2023 for results and 2024 with final results.
One more thing to note MAT90001 will not get NCE or NME on Astrazeca's Epanova already has Oranged Booked with the FDA a DPA drug product. So at this point in time they have to defend there one patent against generics from day one. While Vascepa which now has NCE is safe from generic filers unitl 2020 with HW.
So with a whole 5 years left on it's patent and having to try to take marked share from an already well established Vascepa. I just don't see a big pharma taking that kind of a chance.
Are you kidding me. Here we go with another way of saying somebody knows something, but trying to sound intelligent about it. Really go back to Yahoo.
Ziploc,
That is exactly what I think. They want to get to oral arguments and once it looks like the judge would side with the FDA no jurisdiction go with we were financially harmed by the FDA hear can we sue them. They could put a price tag on it and I see why the FDA would want the judge to rule on this now without oral arguments.
Wow is this saying that the FDA was pissed at JZ for shoting off his mouth and that is why we are were we are today with them?
Very interesting statement. Thanks for sharing and keep up the great work.
Here is a list of the patents I am currently trying to read through when I get free time. Feel free to read through these on your own. They are very dry and hard to understand. I found these doing a quick search on the uspto web page.
1 9,072,715 Full-Text Stable pharmaceutical composition and methods of using same
2 9,060,983 Full-Text Stable pharmaceutical composition and methods of using same
3 9,060,982 Full-Text Stable pharmaceutical composition and methods of using same
4 9,057,617 Full-Text Enhanced identification of interesting points-of-interest
5 9,057,616 Full-Text Enhanced identification of interesting points-of-interest
6 9,056,088 Full-Text Pharmaceutical compositions comprising fatty acids
7 9,046,235 Full-Text LED renewable energy lighting unit having a polygonal solar panel configuration about a horizontal or vertical pole
8 8,969,514 Full-Text Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
9 8,940,840 Full-Text Method for bonding active molecules onto a carrier, active element obtained by said method, and chemical composition for implementing said method
10 8,901,075 Full-Text Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
11 8,779,090 Full-Text Methods and compositions for the treatment of heart failure and other disorders
12 8,772,309 Full-Text Pharmaceutical formulation of apomorphine for buccal administration
13 8,765,725 Full-Text Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
14 8,762,053 Full-Text Enhanced identification of interesting points-of-interest
15 8,741,336 Full-Text Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, Alzheimer'S disease, sleep disorders, Parkinson'S disease, AIDS, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
16 8,716,224 Full-Text Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
17 8,710,041 Full-Text Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy
18 8,709,475 Full-Text Stable pharmaceutical composition and methods of using same
19 8,703,185 Full-Text Stable pharmaceutical composition and methods of using same
20 8,691,871 Full-Text Methods of treating mixed dyslipidemia
21 8,680,144 Full-Text Methods of treating mixed dyslipidemia
22 8,669,245 Full-Text Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
23 8,664,354 Full-Text Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
24 8,663,662 Full-Text Stable pharmaceutical composition and methods of using same
25 8,642,077 Full-Text Stable pharmaceutical composition and methods of using same
26 8,623,406 Full-Text Stable pharmaceutical composition and methods of using same
27 8,620,579 Full-Text Enhanced identification of interesting points-of-interest
28 8,618,166 Full-Text Methods of treating mixed dyslipidemia
29 8,617,594 Full-Text Stable pharmaceutical composition and methods of using same
30 8,617,593 Full-Text Stable pharmaceutical composition and methods of using same
31 8,613,945 Full-Text Stable pharmaceutical composition and methods of using same
32 8,589,069 Full-Text Enhanced identification of interesting points-of-interest
33 8,569,246 Full-Text Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
34 8,566,029 Full-Text Enhanced identification of interesting points-of-interest
35 8,563,608 Full-Text Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
36 8,551,521 Full-Text Stable pharmaceutical composition and methods of using same
37 8,546,372 Full-Text Methods of treating hypertriglyceridemia
38 8,524,698 Full-Text Methods of treating hypertriglyceridemia
39 8,518,929 Full-Text Methods of treating hypertriglyceridemia
40 8,501,225 Full-Text Stable pharmaceutical composition and methods of using same
41 8,497,348 Full-Text Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
42 8,455,472 Full-Text Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
43 8,454,994 Full-Text Stable pharmaceutical composition and methods of using same
44 8,445,013 Full-Text Stable pharmaceutical composition and methods of using same
45 8,445,003 Full-Text Stable pharmaceutical composition and methods of using same
46 8,440,650 Full-Text Methods of treating hypertriglyceridemia
47 8,433,512 Full-Text Enhanced identification of interesting points-of-interest
48 8,431,560 Full-Text Methods of treating hypertriglyceridemia
49 8,426,399 Full-Text Methods of treating hypertriglyceridemia
50 8,415,335 Full-Text Methods of treating hypertriglyceridemia
Yes of course why do you think Amarin went after AZ before they could launch Epanova for damages. What I am not sure of and searching against this new OB DPA formula, which sts, BioB and myself feel is a complete violation by the FDA to allow these AZ patents to be put in OB, is if the patent held by Amarin also states DPA.
I couldn't agree with you more. I was just trying to shine some light on how AZ is trying to circumvent the amrn patent. Even if they do they are still putting a crap solution out there.
I assume by adding DPA as part of the active moiety it gets around the IP, and since the AZ patent is in the OB under Epanova one can only assume somehow it does?
I am surprised they would even consider launching this crap.
Ziploc,
Actually I was thinking this could be the same thing as Lovaza and for all we know DPA in these small amounts may have been in the unknown part of Lovaza's formulation. Yes I totally agree this is an ineffective product compared to Vascepa.
The question is even if AZ circumvents amrn patents and the FDA allows this crap. Do they go ahead and market it or do think vascepa sales reps will be able to show it is just another version of Lovaza or DS fish oil. Unlike the uniqueness of pure EPA.
Snipits taken from the AZ patent:
A pharmaceutical composition, comprising: EPA, in a weight percent amount of 50% to 60%; DHA, in a weight percent amount of 17% to 23%; DPA, in a weight percent amount of 1% to 8%; wherein at least 90% by weight of the polyunsaturated fatty acid in the composition is present in the free acid form.
In a first aspect, the present disclosure provides DPA-enriched pharmaceutical compositions of omega-3 polyunsaturated fatty acids in free acid form. Enrichment in DPA content was an unintended and unexpected consequence of the commercial-scale production process. These DPA-enriched pharmaceutical compositions have been demonstrated to have exceptional pharmacological and clinical efficacy in in vitro experiments and in human clinical trials.
A further challenge in designing an optimal composition is variation in bioavailability of orally administered PUFA compositions. Absorption of PUFAs in the form of ethyl esters is known, for example, to depend on the presence of pancreatic lipase, which is released in response to ingested fats. Absorption of PUFA ethyl esters is therefore inefficient, and is subject to substantial variation, both among subjects and in any individual subject, depending on dietary intake of fat. See Lawson et al., "Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl esters," Biochem Biophys Res Commun. 152:328-35 (1988); Lawson et al., Biochem Biophys Res Commun. 156:960-3 (1988). Absorption is particularly reduced in subjects on low-fat diets, a diet advocated for subjects with elevated serum triglyceride levels or cardiovascular disease.
Example 7 presents the results of the ECLIPSE clinical trial, an open-label, single dose, randomized 4-way-crossover study comparing the bioavailability of a 4 g dose of Lovaza.RTM. to bioavailability of a 4 g dose of the DPA-enriched pharmaceutical composition of omega-3 PUFA in free acid form described herein (hereinafter, "Epanova.RTM."), under both high fat and low fat dietary conditions. According to the FDA-approved product label, each 1-gram capsule of Lovaza.RTM. contains at least 900 mg of the ethyl esters of omega-3 fatty acids sourced from fish oils, predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA--approximately 465 mg) and docosahexaenoic acid (DHA--approximately 375 mg). The batch of Epanova.RTM. used in the trial comprised 57.3% (a/a) EPA, 19.6% (a/a) DHA, and 6.2% (a/a) DPA, each substantially in free acid form.
______________________________________________________________________
Correct me if I am reading this wrong but it sounds as if AZ has gone back to the FDA and said opps this is really our formulation so sorry for the screw up. So all of our previous testing is still valid we just need to update the formulation part right guys. Since it is the same drug name I would think they still have to inform Amarin 30 days prior to launch, but it does sound like they will be able to launch sooner rather that later?
They also put in the part that this drug goes hand in hand with the FDA low fat diet recommendation better than EPA, which needs fat in the diet to work. I will let JL elaborate more on this especially since EPA does convert to DPA in some amount?
This gets under the Matina's patent which is 160mg to 800mg of DPA and optionally EPA and DHA. This is with an engineered DPA that is supposed to be identical in every way to the natural DPA. Notice since this has happened MTNB as now gone back under a dollar.
Hope this helps and look forward to hearing the views of others.
I need some help with my mothers insurance company. I am trying to get her prescription of V covered by insurance and what a pain. So I want to write a letter that her doctor can sign and add any info and send to insurance company. She fits in anchor population. Some very smart person a while back put out a post to tell the insurance company tried niacin and phenofibrates but can not tolerate. Also cannot take L for Gen L because her cholesteral is already to high.
What I am after is does anyone have a letter example I could use to draft a letter for her doctor to send to her insurance company?
1-16-15 Democratic Senate last day in office.
sts66,
Thank you I don't know how I missed it but I did and I read hear quite often and want to share this info with my parents.
Thanks again,
zman,
Thank you for the confirmation on CoQ10 I will have to get my parents to take some with there statins.
It had never been my finding to get krill oil cheaper than fish oil and krill always has lower levels of EPA and DHA than fish oil. So I would have to disagree with you on your krill oil idea.
Thanks again for the info,
Anyone read this new article on yahoo.
http://www.theepochtimes.com/n3/1017971-do-you-take-any-of-these-11-dangerous-statins-or-cholesterol-drugs/
It sounds very much like what JL has been preaching for a long time.
However I do not recall hearing about CoQ10 here.
I also find it very interesting in the "Optimizing Your Cholesterol Levels, Naturally" he mentions O3's but slips in "krill oil". You think he might be a NEPT investor or APO.V.
Article is pretty good except for CoQ10 and Krill Oil.
SCRIPTS - 07/11/2014 - From Keystone on Yahoo Msg Board.
.
TRx................Vascepa..............Lovaza................Niaspan
07/11/14..........8,509................54,191.................13,081
07/04/14..........7,714................43,874.................11,674
06/27/14..........8,031................42,081.................13,151
06/20/14..........7,743................40,911.................12,951
06/13/14..........7,742................35,621.................12,958 Less
Here are people who get it.
http://health.yahoo.net/experts/dayinhealth/simple-tests-heart-attack-risk-could-save-lives-and-180-million
Would love to hear if anyone on Vascepa has taken this blood test before and after for some comparison numbers.